Alnylam and Blackstone Enter into Financing Deal for Up to 2 Billion to Accelerate RNAi Therapeutics

Apr 16, 2020 | Investor Watch, News

Alnylam and Blackstone Enter into Financing Deal for Up to 2 Billion to Accelerate RNAi Therapeutics

Alnylam and investment firm Blackstone Life Sciences have entered into a broad strategic collaboration worth up to $2 billion to support the advancement of Alnylam’s RNA interference (RNAi) drugs. 

As part of the deal, Blackstone will acquire 50 percent of the royalties owed to Alnylam on global sales of inclisiran, a twice-a-year, subcutaneously injected RNAi therapeutic for the treatment of hypercholesterolemia. Other components of the deal include up to $750 million in a first lien senior secured term loan led by GSO; up to $150 million from Blackstone Life Sciences for development of Alnylam’s cardiometabolic programs vutrisiran and ALN-AGT (to be established based upon a non-binding letter of intent) and $100 million purchase of Alnylam common stock. 

Inclisiran is currently under review by the U.S. Food and Drug Administration. Results from two phase 3 trials, ORION-10 and ORION-11 were published in The New England Journal of Medicine in March of 2020. the Both trials showed treatment with inclisiran led to reductions in LDL cholesterol levels of approximately 50%.

Alnylam and The Medicines Company entered into a strategic alliance for inclisiran in 2013. Novartis acquired inclisiran when it purchased The Medicines Company for $9.7 billion in November of 2019.

Source: Alnylan

0 Comments

Pin It on Pinterest